CSI Market
Sign In | Register

Zyla Life Sciences (EGLT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EGLT Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Zyla Life Sciences's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2020)
3 Months 		(Dec 31 2019) (Sep 30 2019) (Jun 30 2019) (Mar 31 2019)
Operating Activities
Income107.24
Depreciation & amortization0.20
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.34
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.13
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Amortization Of Marketable Securities Premium Discount-0.01
Gain Loss On Derivative Instruments Net Pretax-
Increase Decrease In Right Of Use Assets-
Increase Decrease In Deposit And Other Assets0.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable4.58
Increase (Decrease) in Accounts Payable0.10
Increase (Decrease) in Accrued Liabilities5.17
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.22
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-121.15
Discontinued operations0.00
Net Cash flow from Operating Activities0.82
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Deposits For Purchases Of Property And Equipment-
Payments For Purchase Of Intangible Rights-
Payments For Purchase Of License Rights-
Deposits For Purchases Of Property And Equipment-
Proceeds From Sale Of Investments-
Proceeds From Maturity And Collections Of Investments-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-19.10
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Initial Public Offering Net-
Proceeds From Issuance Of Private Placement Net-
Capital Expenditures Incurred But Not Yet Paid-
Conversion Of Stock Amount Issued-
Payments For Royalties On Senior Secured Notes Payable-
Proceeds From Issuance Of Common Stock And Warrants-
Payment Of Tax Withholdings On Restricted Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-19.10
Effect of exchange rate on cash flow0.01
Discontinued operations0.00
Free Cash Flow0.82
Total Cash Flow-18.28
4 historic quarters locked

Sign in to unlock the full Zyla Life Sciences cash flow history.

Sign In Create Free Account

About EGLT Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.